Modified hGH 176-191 fragment (lipolytic)
Synthetic fragment of growth hormone's fat-metabolism tail, stabilized with an added tyrosine; studied for fat loss.
| Class / type | Modified hGH 176-191 fragment (lipolytic) |
|---|---|
| Category | Metabolic & Weight |
| Status (Jul 2026) | Research use only |
Believed to mimic hGH's lipolytic action (stimulates hormone-sensitive lipase, inhibits acetyl-CoA carboxylase) WITHOUT raising IGF-1.
Obesity / fat reduction; cartilage/osteoarthritis research.
Preclinical fat-oxidation/weight loss; theoretically avoids hGH blood-sugar and growth side effects.
Human efficacy inconsistent/unproven; not approved; limited long-term safety; gray-market purity risk.
Idea of 'targeted' fat loss without systemic HGH effects; described as mild/well-tolerated anecdotally.
NOT FDA-approved. FDA Category 2 bulk substance (compounding restricted). Research-use-only. Same fragment family as HGH Frag 176-191.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.